Basque enterprise blog Receive daily information of interest to your company

2 October, 2019
VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan

in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials

 

VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its strategic plan, which highlights the construction of three new cleanrooms and the incorporation of new equipment that will multiply its production capacity substantially. VIVEbiotech will now have 600 square meters of clean rooms with 8 nanobioreactors and two large capacity bioreactors.

Thanks to this growth, in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials in which hundreds of patients participate, as well as to attend the commercial scale production of any gene therapy product that uses lentivirus. The trend of the gene therapy market is growing and with the new infrastructure VIVEbiotech will be able to respond to this reality.

The capital increase has been endorsed by VIVEbiotech´s private partners who continue with their commitment to the company and its future. Easo Ventures and Inveready are the new shareholders, the latter being a venture capital fund with extensive experience in biotechnology.

VIVEbiotech is already producing lentiviral vectors for 16 gene therapy projects, 6 of them with CAR-Ts. Customers are located in European countries, the United States, Israel and Australia.

Bio Health 3 February, 2020
VIVEbiotech SL new member of the Board of Directors of the Spanish Bioindustry Association (AseBio)

AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Leer más

Bio Health 17 June, 2019
VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office

LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the...Leer más

Bio Health 28 January, 2019
Columbus launches a €70 million fund for biomedicine

With the new investment fund, the managers plan to build two new plants in San...Leer más

Linkedin

Daily information segmented according to business
sectors and countries of interest to make the most competitive
decisions

Latest news about New Subsidies

For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.

You’re interested, right?